A Clinical Trial to Demonstrate Clinical Efficacy on Cognitive, Neuropsychiatric and Functional Outcomes of Ambroxol in New and Early Patients With Prodromal and Mild Dementia With Lewybodies
Latest Information Update: 26 Dec 2023
Price :
$35 *
At a glance
- Drugs Ambroxol (Primary)
- Indications Lewy body disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms ANeED
- 18 Dec 2023 Planned number of patients changed from 172 to 180.
- 18 Dec 2023 Planned End Date changed from 1 Dec 2023 to 1 Jul 2025.
- 18 Dec 2023 Planned primary completion date changed from 1 Apr 2022 to 1 Dec 2024.